pages:
-
A Novel Proteolytic System of Pulmonary Inflammation
-
A Novel Regimen to Prevent Malaria and STIs in Pregnant Women with HIV
-
A Novel Role for IGF-1 Receptor in Growth Hormone Action
-
A Novel Role of AhR Mediated Intestinal Injury in Neonates
-
A Novel Source of Mucosal T Cells to Study Immunity in the Female Genital Tract
-
A Novel Stemness Program with Epigenetic Dysregulation in Acute Myeloid Leukemia
-
A Novel Strategy Targeting SRC Tyrosine Kinase for Breast Cancer Metastasis
-
A Novel T-Cell Quiescence Mechanism in Anti-Ovarian Tumor Responses
-
A Novel Therapeutic Approach for Treating WNT-Driven Hepatocellular Carcinoma
-
A Novel Therapeutic Target for Treating Aggressive and Metastatic Hepatocellular Carcinoma
-
A Novel Transcriptional Vulnerability in Acute Myeloid Leukemia
-
A Novel Zebrafish Model of Thrombotic Thrombocytopenic Purpura
-
A Novel Zebrafish Model of Thrombotic Thrombocytopenic Purpura
-
A Nurse-Led Structured Discharge Teaching Intervention for Parents of Newly Diagnosed Pediatric Oncology Patients
-
A Patient Activation Intervention to Improve Bone Health in Older Adults
-
A Phase 1 / 2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma
-
A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma
-
A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
-
A Phase 2 Multicenter, Single-Arm, Open-Label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (Revlimid®) in Pediatric Subjects from 1 To < 18 Years of Age with Relapsed or Refractory Acute Myeloid Leukemia
-
A Phase 2 Proof-of-concept Study to Evaluate the Efficacy and Safety of MEDI3902 in Mechanically Ventilated Patients for the Prevention of Nosocomial Pneumonia Caused by Pseudomonas aeruginosa
-
A Phase 2/3 Open-label, Randomized, Sequential Dose Escalation Cohort Study of T2307 Versus Standard of Care in Treatment of Subjects with Candidemia due to Candida Auris and other Drug-resistant Candida Species: An Adaptive Design Study
-
A Phase 2A Study to Evaluate the Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients with Acute Liver Failure/Severe Acute Liver Injury (STOP-ALF)
-
A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC # 606869) in the Very High Risk Stratum
-
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of LY3819253 in Preventing SARS-CoV-2 Infection and COVID-19 in Skilled Nursing and Assisted Living Facility Residents and Staff - a NIAID and Lilly Collaborative Study
-
A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients with High Grade Gliomas and Severe Treatment-Related CD4 Lymphopenia after Concurrent Radiation and Temozolomide
-
A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects with Recurrent High-Grade Glioma Undergoing Standard. Repeated Temozolomide Treatment (TAU-2010-1)
-
A Phase I Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA) in Children with Relapsed Refractory Solid Tumors
-
A Phase I Study to Evaluate the Safety and Immunogenicity of HPV 16 L2 11-200
-
A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination with Anti-PD-1 in Patients with Recurrent GBM
-
A Phase I Trial of IRS-1 HSV C134 Administered Intratumorally in Patients with Recurrent Malignant Glioma
pages:
